Purple Biotech Reports Q3 2026 Results; Net Loss $1.0M on Lower Operating Expenses
Purple Biotech Ltd. reported a net loss of $1.0 million for Q3 2026, compared to a net loss of $1.3 million for Q3 2025, as operating expenses declined. Operating loss decreased to $1.1 million from $1.4 million, driven by lower R&D and G&A spending. The company ended Q3 2026 with $5.1 million in cash and cash equivalents, which management expects to fund operations through late-2027. The company also announced leadership transition with Isaac Israel appointed as Interim CEO following the departure of Gil Efron.
Key takeaways
Net loss: Purple Biotech reported Q3 2026 net loss of $1.0 million, compared to $1.3 million net loss in Q3 2025, as total operating expenses declined.
Operating loss: Operating loss decreased to $1.1 million from $1.4 million, driven by lower R&D expenses ($0.4 million vs $0.6 million) and lower G&A expenses ($0.7 million vs $0.8 million).
Cash position: Cash, cash equivalents and short-term deposits were $5.1 million as of September 30, 2026, expected to provide runway through late-2027.
Leadership change: Isaac Israel appointed as Interim CEO following departure of former CEO Gil Efron.
Pipeline update: IND application for lead candidate IM1240 planned for 2027, with first-in-human study to follow.
Patent granted: U.S. patent covering tri-specific antibody constructs and methods of use granted for CAPTN-3 platform in September 2026.
Conference presentation: IM1240 data selected for plenary oral presentation at 38th EORTC-NCI-AACR Symposium on November 20, 2026.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow PPBT in real time
Get material earnings, filing, IR, and earnings-call alerts by email.